DAFTAR PUSTAKA

1. Engel, A. G. MD. Myasthenia Gravis and Myasthenic Syndromes. Ann

Neurol 16: Page: 519-534. 1984.
2. Harsono, 2005. Buku Ajar Neurologi Klinik PERDOSSI. Yogyakarta: Gadjah
Mada University Press. Hal. 327-332

3. Christensen P.B., Jensen T.S., Tsirropoulus I., et.al., Mortality and survival in
myasthenia gravis: a Danish population based study. J Neurol Neurosurg
Psychiatry 2003; 64: 78-63.

4. Vernino S., Lennon V.A., Autoantibody profiles and neurological correlations

of thymoma. Clin Cancer Res 2004 May; 18: 678-80.

5. Berrih S., Morel E., Gaud C., Raimond F., LeBrigand H., Bach J.F., Anti-
AChR antibodies,thymic histology, and T cell subsets in myasthenia gravis.
Neurology 2001 March;34:66-71.

6. Snell, Richard S., 2007. Neuro Anatomi Klinik ed. 5. EGC. Jakarta.Murray,
R.K, Granner, D.K, Mayes, P.A.2008. Biokimia Harper: Dasar Biokimia
Beberapa Kelainan Neuropsikiatri. Edisi 29. EGC. Jakarta.

7. Miastenia Gravis Indonesia. 2017. http://www.mgindonesia.org/myasthenia-

gravis.html. Diakses pada tanggal 08 April 2017

8. Price, Sylvia A. Wilson, Lorraine M., 2006. Patofisiologi Konsep Klinis

Proses-Proses Penyakit ed. 6 vol.2. EGC. Jakarta.

9. Mardjono, M., 2004. Neurologi Klinis Dasar 9th ed. Dian Rakyat, Jakarta.

10. Ngoerah, I. G. N. G, 1991. Dasar-dasar Ilmu Penyakit Saraf. Airlanga

University Press.

11. Richman D.P., Agius M.A., Treatment of myasthenia gravis. Neurology. 2003
December; 61: 1652-1659.
12. Ronager J., Ravnborg M., Hermansen I., Vorstrup S., Immunoglobulin
treatment versus plasma exchange in patients with chronic moderate to severe
myasthenia gravis. Artif Organs 2001 March;25:967-973.